Payment overview · 2025
General Payments
$103,362.24
423 reported records · 49 companies
Healthcare provider profile · identity verified
Robert Matthew Carlile, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · SUMMERVILLE, SC · NPI 1740575307
Verified facts
What the public records show
CMS Open Payments records show Robert Matthew Carlile, M.D. received $103,362.24 in general payments during 2025 across 423 reported records.
Lilly USA, LLC accounted for 48.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 60 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Gocovri, Ingrezza, Nuplazid, Nurtec Odt, Qulipta, Rexulti, Rystiggo, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Nuplazid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Rytary by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rexulti by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gocovri as an associated drug or biological on 3202 records involving 1029 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Gocovri by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Nurtec Odt by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APTIOM as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Aptiom by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Gammagard Liquid by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Austedo by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rystiggo as an associated drug or biological on 11914 records involving 4077 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rystiggo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $50,422.04 | 48.8% | 66 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22,818.74 | 22.1% | 50 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $13,680.84 | 13.2% | 20 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $11,313.70 | 10.9% | 23 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $826.61 | 0.8% | 33 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $426.78 | 0.4% | 20 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $360.83 | 0.3% | 22 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $339.62 | 0.3% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $286.83 | 0.3% | 25 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $235.10 | 0.2% | 16 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $208.77 | 0.2% | 10 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $203.36 | 0.2% | 17 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $191.61 | 0.2% | 16 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $186.54 | 0.2% | 12 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $178.32 | 0.2% | 12 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $127.64 | 0.1% | 6 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $118.57 | 0.1% | 4 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $118.34 | 0.1% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $117.76 | 0.1% | 5 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $94.80 | 0.1% | 4 | 2025 |
| F. Hoffmann-La Roche AG | Unresolved — no canonical attribution shown | $80.00 | 0.1% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $79.52 | 0.1% | 4 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $79.02 | 0.1% | 3 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $72.39 | 0.1% | 2 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $66.94 | 0.1% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $60.30 | 0.1% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $56.28 | 0.1% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $54.93 | 0.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $44.66 | 0.0% | 2 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $44.27 | 0.0% | 3 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $43.80 | 0.0% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $42.03 | 0.0% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $35.65 | 0.0% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $34.48 | 0.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $29.13 | 0.0% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.47 | 0.0% | 1 | 2025 |
| Ultragenyx Pharmaceutical Inc. | Unresolved — no canonical attribution shown | $26.50 | 0.0% | 1 | 2025 |
| Eli Lilly Export S.A. Puerto Rico Branch | Unresolved — no canonical attribution shown | $25.00 | 0.0% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$24.72 | 0.0% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $22.63 | 0.0% | 1 | 2025 |
| Sonex Health, Inc. | Unresolved — no canonical attribution shown | $21.25 | 0.0% | 1 | 2025 |
| InSightec,Inc | Unresolved — no canonical attribution shown | $19.08 | 0.0% | 1 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.17 | 0.0% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $17.76 | 0.0% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.15 | 0.0% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.94 | 0.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.56 | 0.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.91 | 0.0% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $13.90 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $68,964.50 | 42 |
| Consulting Fee | $16,835.00 | 7 |
| Travel and Lodging | $10,075.32 | 23 |
| Food and Beverage | $7,414.42 | 350 |
| Education | $73.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Eli Lilly Export S.A. Puerto Rico Branch, Lilly USA, LLC | $46,101.56 | 56 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16,741.44 | 36 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14,179.91 | 30 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $13,680.84 | 20 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $11,313.70 | 23 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $826.61 | 33 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $426.78 | 20 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $239.84 | 15 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $208.77 | 10 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $180.96 | 11 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $179.29 | 12 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $178.63 | 12 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $145.20 | 12 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $145.20 | 12 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $141.63 | 13 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $127.64 | 6 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $127.05 | 13 | 2025 |
Source payment records
|
|||||
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $119.68 | 1 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | Sumitomo Pharma America, Inc. | $118.57 | 4 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $118.34 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $116.77 | 7 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $114.76 | 11 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $104.38 | 5 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $101.57 | 9 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $94.80 | 4 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $91.59 | 6 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $88.60 | 6 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $79.52 | 4 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $79.02 | 3 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $78.75 | 5 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $72.39 | 2 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $66.94 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $64.56 | 3 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $55.31 | 2 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $55.31 | 2 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $54.93 | 3 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $51.97 | 3 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $44.66 | 2 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $44.27 | 3 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $43.80 | 2 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $42.03 | 2 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $35.65 | 2 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $34.48 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $29.40 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $29.13 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $28.47 | 1 | 2025 |
Source payment records
|
|||||
| Dojolvi Normalized: dojolvi |
Drug | Ultragenyx Pharmaceutical Inc. | $26.50 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $24.72 | 1 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $23.24 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| SX-ONE MICROKNIFE Normalized: sx one microknife |
Device | Sonex Health, Inc. | $21.25 | 1 | 2025 |
Source payment records
|
|||||
| Exablate Normalized: exablate |
Device | InSightec,Inc | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $15.56 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 65 | exact normalized | Medicare Part D |
| Gocovri gocovri |
2025 | Gocovri | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rystiggo rystiggo |
2025 | Rystiggo | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
65 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
42 | 14 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Gocovri open payments reported associated product |
CMS Open Payments — General Payments 3202 supporting records · 1029 recipient NPIs · example record 1241843637 |
Gocovri · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | APTIOM open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1176658319 |
Aptiom · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Rystiggo open payments reported associated product |
CMS Open Payments — General Payments 11914 supporting records · 4077 recipient NPIs · example record 1224348577 |
Rystiggo · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Memantine Hcl | Memantine Hcl | 384 | 131 |
| Donepezil Hcl | Donepezil Hcl | 319 | 98 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 272 | 98 |
| Gabapentin | Gabapentin | 249 | 88 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 231 | 83 |
| Levetiracetam | Levetiracetam | 153 | 41 |
| Pregabalin | Pregabalin | 149 | 49 |
| Amitriptyline Hcl | Amitriptyline Hcl | 125 | 40 |
| Quetiapine Fumarate | Quetiapine Fumarate | 116 | 46 |
| Sertraline Hcl | Sertraline Hcl | 107 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 35 |
| Topiramate | Topiramate | 93 | 37 |
| Trazodone Hcl | Trazodone Hcl | 88 | 42 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 75 | 14 |
| Buspirone Hcl | Buspirone Hcl | 68 | 32 |
| Botox | Onabotulinumtoxina | 65 | 21 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 59 | 16 |
| Austedo | Deutetrabenazine | 57 | suppressed |
| Baclofen | Baclofen | 57 | 18 |
| Mirtazapine | Mirtazapine | 52 | 26 |
| Sumatriptan Succinate | Sumatriptan Succinate | 52 | 12 |
| Oxcarbazepine | Oxcarbazepine | 51 | 16 |
| Nuplazid | Pimavanserin Tartrate | 50 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 48 | suppressed |
| Diazepam | Diazepam | 47 | 30 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 47 | 17 |
| Rizatriptan | Rizatriptan Benzoate | 47 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 20 |
| Tramadol Hcl | Tramadol Hcl | 45 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 44 | 20 |
| Atorvastatin Calcium | Atorvastatin Calcium | 42 | 16 |
| Emgality Pen | Galcanezumab-Gnlm | 42 | suppressed |
| Rytary | Carbidopa/Levodopa | 42 | 14 |
| Lacosamide | Lacosamide | 41 | 13 |
| Phenobarbital | Phenobarbital | 40 | suppressed |
| Ingrezza | Valbenazine Tosylate | 37 | suppressed |
| Primidone | Primidone | 37 | 15 |
| Nurtec Odt | Rimegepant Sulfate | 36 | suppressed |
| Qulipta | Atogepant | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Amantadine | Amantadine Hcl | 29 | 11 |
| Carbamazepine Er | Carbamazepine | 29 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 28 | suppressed |
| Rivastigmine | Rivastigmine | 27 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 27 | suppressed |
| Ubrelvy | Ubrogepant | 26 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Alprazolam | Alprazolam | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Meloxicam | Meloxicam | 21 | suppressed |
| Rexulti | Brexpiprazole | 21 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 21 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 19 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 16 | suppressed |
| Dalfampridine Er | Dalfampridine | 16 | suppressed |
| Dexamethasone | Dexamethasone | 16 | 13 |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 16 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 16 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Gocovri | Amantadine Hcl | 15 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 15 | suppressed |
| Nourianz | Istradefylline | 15 | suppressed |
| Modafinil | Modafinil | 14 | suppressed |
| Omeprazole | Omeprazole | 14 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 14 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 13 | suppressed |
| Northera | Droxidopa | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 12 | suppressed |
| Nucynta | Tapentadol Hcl | 12 | suppressed |
| Kesimpta Pen | Ofatumumab | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Rystiggo | Rozanolixizumab-Noli | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $103,362.24 · 423 records | Lilly USA, LLC | ACTHAR, AMPYRA, AUSTEDO XR, Auvelity, BOTOX, BRIUMVI, Briviact, COBENFY, CREXONT, Dojolvi, EPIDIOLEX, Exablate, FYCOMPA, GOMEKLI, Gamunex-C, Gocovri, HYQVIA, Hizentra, INBRIJA, INGREZZA, INTELLIS ADAPTIVESTIM, KESIMPTA, KEVEYIS, KISUNLA, LEQEMBI, LEQVIO, Mavenclad, NUPLAZID, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), ONPATTRO, ORGOVYX, Ocrevus Zunovo, PANZYGA, PONVORY, PRECIVITYAD2, PURIFIED CORTROPHIN GEL, QULIPTA, QUTENZA, Qelbree, REXULTI, Radicava, Rystiggo, SX-ONE MICROKNIFE, Symbravo, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VUMERITY, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, WAINUA, Xeomin, ZAVZPRET, ZEPOSIA | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error